Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 108 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Interventions
RMC-6291
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Springdale, Arkansas • Orange, California • Sacramento, California + 10 more
Conditions
Ovarian Neoplasm, Uterine Neoplasm
Interventions
Informational Intervention, Questionnaire Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Biopsy Proven Non Small Cell Lung Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Colorectal Cancer, Rectal Cancers, Gynecological Malignancy Requiring Definitive Radiotherapy
Interventions
CT scan
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Early Phase 1 Interventional Results available

Gynecological Sentinel Lymph Nodes CEUS

NCT05105087
Conditions
Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Perflubutane Microbubble, Contrast-Enhanced Ultrasound
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
Interventions
PM01183 + paclitaxel +/- bevacizumab
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer, Ovarian Cancer, Gynecologic Neoplasm, Endometrial Cancer
Interventions
Paxman Scalp Cooling Device
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Malignant Female Reproductive System Neoplasm
Interventions
Infection Prophylaxis and Management
Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
19 Years and older · Female only
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Breast Cancer, Gynecologic Cancers, Mitochondrial Function
Interventions
Not listed
Lead sponsor
University of South Carolina
Other
Eligibility
20 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

PSMA PET and MRI in Gynecological Cancers

NCT03302156
Conditions
Gynecologic Cancer
Interventions
PSMA-based 18F-DCFPyL PET tracer
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Gynecologic Cancer, Genitourinary Cancer
Interventions
Airway Pressure Release Ventilation, Conventional Mechanical Ventilation
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Stomach Cancer, Colorectal Cancer, Appendiceal Cancer, Ovarian Cancer, Uterine Cancer, Cervical Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
HIPEC, Mitomycin c, CDDP 50, CDDP 75, Doxorubicin
Device · Drug
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Teaneck, New Jersey
Conditions
Gynecologic Surgical Procedures
Interventions
Rectus sheath block, Thoracic Epidural Analgesia, Liposomal bupivacaine, Bupivacaine Hydrochloride, Bupivacaine-Hydromorphone Cassette
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Transvaginal Ultrasound Training for Obstetrics and Gynecology Residents

NCT02890914
Conditions
Ovarian Cysts
Interventions
Transvaginal Ultrasound Educational DVD
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • West Reading, Pennsylvania • Wynnewood, Pennsylvania
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Interventions
RMC-6236
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
21
States / cities
Orange, California • Santa Monica, California • Tampa, Florida + 16 more
Conditions
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer, Metastatic Vulvar Cancer, Metastatic Endometrial Cancer, Recurrent Cervical Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Recurrent Endometrial Cancer
Interventions
Durvalumab, Tremelimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer, Solid Tumor
Interventions
Avutometinib (VS-6766) + defactinib
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Orlando, Florida • New Orleans, Louisiana • Albuquerque, New Mexico + 1 more
Completed Phase 2 Interventional Results available

Image-Guided Gynecologic Brachytherapy

NCT01399658
Conditions
Cervical Cancer, Uterine Cancer, Vaginal Cancer, Carcinoma of the Vulva
Interventions
Image-guided brachytherapy, 3'-Deoxy-3'-18f-Fluorothymidine
Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Oral rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
36
States / cities
Anchorage, Alaska • Tucson, Arizona • Fullerton, California + 28 more
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
6
States / cities
San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more
Conditions
Ovarian Cancer, Uterine Cancer
Interventions
Guided imagery and music therapy, White Noise, No intervention
Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
19 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Gynecologic Cancer, Gynecologic Disease, Gynecological Surgery, Uterine Cancer
Interventions
Uterine Lavage
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
10-15 minute, Audio-Recorded Guided Mediation Practices
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Terminated Phase 2 Interventional Results available

Trisenox® in Women With Metastatic Endometrial Cancer

NCT01184053
Conditions
Endometrial Carcinoma
Interventions
Arsenic trioxide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 3 Interventional Accepts healthy volunteers Results available

An Endometrial Cancer Chemoprevention Study of Metformin

NCT01697566
Conditions
Gynecology
Interventions
Metformin, Placebo, Endometrial Biopsy, Lifestyle Intervention, Questionnaires
Drug · Other · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Houston, Texas